Rep. Gilbert Cisneros Purchases Shares in BridgeBio Pharma

Cisneros disclosed a purchase of BridgeBio Pharma shares valued between $1,001 and $15,000.

Written by Trueearnings · Published Jun 12, 2026, 9:21 PM EDT · Updated Jun 15, 2026, 4:02 AM EDT

Key Points

Rep. Gilbert Cisneros bought BridgeBio Pharma shares, valued between $1,001 and $15,000, as disclosed on June 9, 2026.
BridgeBio Pharma, trading at $67.14, has a market cap of $13.08 billion and a forward P/E of 134.9.
Insiders and analysts show active interest, with CEO Neil Kumar selling shares and analysts maintaining 'buy' ratings.

Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical

All-time return -1.0% S&P 500 +93.0%

vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

On June 9, 2026, Rep. Gilbert Cisneros disclosed a purchase of BridgeBio Pharma, Inc. shares, valued between $1,001 and $15,000. This transaction was reported as part of the STOCK Act requirements, which mandate the disclosure of stock trades by members of Congress.

BridgeBio Pharma Stock Snapshot

Shares of NasdaqGS:BBIO traded at $67.14 recently. BridgeBio Pharma, Inc. is a biotechnology company based in Palo Alto, California, with a market capitalization of about $13.08 billion. The company has a forward P/E ratio of 134.9 and a beta of 0.975, indicating moderate volatility. Over the past year, the stock has ranged from $38.58 to $84.94, with recent moving averages of $70.28 (50-day) and $67.14 (200-day).

Insider Buying and Selling at BridgeBio Pharma, Inc.

Insider activity at BridgeBio Pharma has been notable. CEO Neil Kumar sold 40,000 shares at an average price of $67.88 on June 5, 2026, as part of a planned sale. Earlier, on May 16, 2026, Kumar bought 71,215 shares, showing active involvement in the company's stock. Additionally, President and CFO Thomas Trimarchi sold 22,781 shares at $66.13 on May 16, 2026.

Analysts Set New Price Targets

BridgeBio Pharma has caught the attention of analysts. On June 3, 2026, Canaccord Genuity initiated coverage with a 'buy' rating and a $104 price target. HC Wainwright & Co. maintained a 'buy' rating with a $110 target on May 11. The consensus among 23 analysts is a 'strong buy,' with an average price target of $102.71.

About BridgeBio Pharma

BridgeBio Pharma, Inc., founded in 2015, is a biopharmaceutical company focused on developing treatments for genetic diseases. The company, headquartered in Palo Alto, California, is led by CEO Dr. Neil Kumar and employs 834 people. BridgeBio develops a range of medicines, including those for cardiomyopathy, molybdenum cofactor deficiency, and genetic bone disorders.

Bottom Line

Rep. Gilbert Cisneros's purchase of BridgeBio Pharma shares adds to the interest in the company from both insiders and analysts. While the 13F filings are backward-looking, this disclosure highlights ongoing interest in the biotech sector. Investors often track such moves for insights into potential trends and market sentiment.